Highlights of This Issue 1

SPECIAL FEATURES

CCR Translations

3  CD137 as a Biomarker for Tumor-Reactive T Cells: Finding Gold in the Desert
   Yuwen Zhu and Lieping Chen
   See related article, p. 44

6  Targeting Metabolic Scavenging in Pancreatic Cancer
   Costas A. Lyssiotis and Lewis C. Cantley
   See related article, p. 120

CCR Perspectives in Drug Approval

9  Radium Ra 223 Dichloride Injection: U.S. Food and Drug Administration Drug Approval Summary

CCR Drug Updates

15  Trastuzumab Emtansine: A Novel Antibody–Drug Conjugate for HER2-Positive Breast Cancer
   Ian Krop and Eric P. Winer

Molecular Pathways

21  Molecular Pathways: SWI/SNF (BAF) Complexes
   Are Frequently Mutated in Cancer—Mechanisms and Potential Therapeutic Insights
   Xiaofeng Wang, Jeffrey R. Haswell, and Charles W.M. Roberts

28  Molecular Pathways: Sterols and Receptor Signaling in Cancer
   Linara Gabitova, Andrey Gorin, and Igor Astsaturov

Review

35  Noncoding RNAs in Prostate Cancer: The Long and the Short of It
   Eva M. Bolton, Alexandra V. Tuzova, Anna L. Walsh, Thomas Lynch, and Antoinette S. Perry

HUMAN CANCER BIOLOGY

44  CD137 Accurately Identifies and Enriches for Naturally Occurring Tumor-Reactive T Cells in Tumor
   Qunrui Ye, De-Gang Song, Mathilde Foussin, Tori Yamamoto, Andrew Best, Chunsheng Li, George Coukos, and Daniel J. Powell Jr. See related article, p. 3

56  αB-Crystallin: A Novel Regulator of Breast Cancer Metastasis to the Brain

68  A High Frequency of Activating Extracellular Domain ERBB2 (HER2) Mutation in Micropapillary Urothelial Carcinoma

76  HDM2 Regulation by AURKA Promotes Cell Survival in Gastric Cancer
   Vikas Sehdev, Ahmed Kanaka, Janet Arras, Dunfa Peng, Mohammed Soutto, Jeffrey Eceddy, Alexander Zaika, Abbes Belkhiri, and Wael El-Rifai

87  Discrete Molecular Classes of Ovarian Cancer Suggestive of Unique Mechanisms of Transformation and Metastases
   Nilesh L. Gardi, Tejaswini U. Deshpande, Swapnil C. Kamble, Sagar R. Badhe, and Sharmila A. Bapat

100 Genes Upregulated in Prostate Cancer Reactive Stroma Promote Prostate Cancer Progression In Vivo
   Olga Dakhova, David Rowley, and Michael Ittmann

CANCER THERAPY: PRECLINICAL

110 The ATP-Competitive mTOR Inhibitor INK128 Enhances In Vitro and In Vivo Radiosensitivity of Pancreatic Carcinoma Cells
   Thomas J. Hayman, Amy Wahba, Barbara H. Rath, Heekyong Rie, Tamalee Kram, Uma T. Shankavaram, Kevin Kamphausen, and Philip J. Tofilon
Targeting of NAD Metabolism in Pancreatic Cancer Cells: Potential Novel Therapy for Pancreatic Tumors
Claudia C.S. Chini, Anaitilde M. Gonzalez Guerrico, Verónica Nin, Juliana Camacho Pereira, Carlos Escande, Maria Theresa Barbosa, and Eduardo N. Chini
See related article, p. 6

Interleukin-7 Mediates Selective Expansion of Tumor-redirected Cytotoxic T Lymphocytes (CTLs) without Enhancement of Regulatory T-cell Inhibition
Serena K. Perna, Daria Pagliara, Aruna Mahendravada, Hao Liu, Malcolm K. Brenner, Barbara Savoldo, and Gianpietro Dotti

Transient Activation of Hedgehog Pathway Rescued Irradiation-Induced Hyposalivation by Preserving Salivary Stem/Progenitor Cells and Parasympathetic Innervation
Bo Hai, Lizheng Qin, Zhenhua Yang, Qingguo Zhao, Lei Shangguan, Xinyu Ti, Yanqiu Zhao, Sangroh Kim, Dharanipathy Rangaraj, and Fei Liu

Gambogic Acid Induces Apoptosis in Imatinib-Resistant Chronic Myeloid Leukemia Cells via Inducing Proteasome Inhibition and Caspase-Dependent Bcr-Abl Downregulation
Xianping Shi, Xin Chen, Xiaofen Li, Shouting Liu, Hongbiao Huang, Ningning Liu, Siyan Liao, Wenbin Song, Ping Zhou, Shunqing Wang, Q. Ping Dou, and Jinbao Liu

AXL Is a Key Regulator of Inherent and Chemotherapy-Induced Invasion and Predicts a Poor Clinical Outcome in Early-Stage Colon Cancer
Philip D. Dunne, Darragh G. McArt, Jaime K. Blayney, Murugan Kalimutho, Samanda Greer, Tingting Wang, Supriya Srivastava, Chee Wee Ong, Ken Arthur, Maurice Loughrey, Kerra Redmond, Daniel B. Longley, Manuel Salto-Tellez, Patrick G. Johnston, and Sandra Van Schaybroeck

Erlotinib, Gefitinib, and Vandetanib Inhibit Human Nucleoside Transporters and Protect Cancer Cells from Gemcitabine Cytotoxicity
Vijaya L. Damaraju, Tara Scriver, Delores Mowles, Michelle Kuzma, Anderson J. Ryan, Carol E. Cass, and Michael B. Sawyer

Neutrophils Promote the Malignant Glioma Phenotype through S100A4
Ji Liang, Yuji Piao, Lindsay Holmes, Gregory N. Fuller, Verlene Henry, Ningyi Tiao, and John F. de Groot

Direct Inhibition of Retinoblastoma Phosphorylation by Nimbolide Causes Cell-Cycle Arrest and Suppresses Glioblastoma Growth
Swagata Karkare, Rishi Raj Chhipa, Jane Anderson, Xiaona Liu, Heather Henry, Anjelika Gasilina, Nicholas Nassar, Jayeeta Roychoudhury, Jason P Clark, Ashish Kumar, Giovanni M. Paulenti, Pradip K. Ghosh, and Biplab Dasgupta

CANCER THERAPY: CLINICAL

A Dose-Escalation Study of SAR3419, an Anti-CD19 Antibody Maytansinoid Conjugate, Administered by Intravenous Infusion Once Weekly in Patients with Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
Vincent Ribrag, Jehan Dupuis, Herve Tilly, Franck Morschhauser, Fabrice Laine, Roch Houot, Corinne Haïoun, Christiane Copie, Andrea Varga, John Lambert, Laurence Hatteville, Samira Ziti-Ljajic, Anne Caron, Sandrine Payrard, and Bertrand Coiffier

Long-lasting Disease Stabilization in the Absence of Toxicity in Metastatic Lung Cancer Patients Vaccinated with an Epitope Derived from Indoleamine 2,3 Dioxygenase
Trine Zeeberg Iversen, Lotte Engell-Noergaard, Rikke Andersen, Stine Kiaer Larsen, Jon Bjoern, Claus Zeyher, Cécile Gouttefangeas, Birthe Moerk Thomsen, Bente Holm, Per thor Straten, Anders Mellemgaard, Mads Hald Andersen, and Inge Marie Svane

Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of SAR245408 (XL147), an Oral Pan-Class I PI3K Inhibitor, in Patients with Advanced Solid Tumors

Tumor Growth Rate Is an Early Indicator of Antitumor Drug Activity in Phase I Clinical Trials
Charles Ferté, Marianna Fernandez, Antoine Hollebecque, Serge Koscielny, Antonin Levy, Christophe Massard, Rastislav Balbeda, Brian Bot, Carlos Gomez-Roca, Clarisse Dromain, Samy Ammar, and Jean-Charles Soria
Plasma MicroRNA Are Disease Response Biomarkers in Classical Hodgkin Lymphoma
Kimberley Jones, Jamie P. Nourse, Colm Keane, Atul Bhatnagar, and Maher K. Gandhi

Modeling RAS Phenotype in Colorectal Cancer Uncovers Novel Molecular Traits of RAS Dependency and Improves Prediction of Response to Targeted Agents in Patients
Justin Guinney, Charles Ferté, Jonathan Dry, Robert McEwen, Gilles Manceau, Kl Kao, Kai-Ming Chang, Claus Bendtsen, Kevin Hudson, Erich Huang, Brian Dougherty, Michel Dacreux, Jean-Charles Soria, Stephen Friend, Jonathan Derry, and Pierre Laurent-Puig

ABOUT THE COVER
The cover shows immunofluorescent labeling of the blood-brain barrier marker GLUT-1 (red) in cultured human brain microvascular endothelial cells. Nuclei (blue) were stained with DAPI. For details, see the article by Malin and colleagues on page 56 of this issue.